Can you introduce us to Canada and your role in the Canadian life sciences ecosystem?
Canada, with its 10 provinces, 3 territories, and a population of approximately 40 million, presents a diverse landscape. Similarly, membership of our organization, BIOTECanada, reflects this diversity. We’re the national association representing the Canadian biotech industry, comprising about 240 member companies. These members span various sectors like industrial, agricultural, and environmental biotech, with a significant focus on the health and life sciences sector. Our membership includes most of the large multinational pharmaceutical companies like Pfizer, AstraZeneca, and Merck, but the majority are early-stage biotech companies born in Canada, emerging from our universities and research centers. These companies are often led by individuals who have discovered a molecule or technology and are working to commercialize it through clinical trials.
Our role extends beyond being the voice of these companies with the government; we also connect them with investors and partners. This involves facilitating business development, especially for small companies, by linking them with large multinational pharma companies and venture capitalists. We strive to aid these early-stage companies in their journey to commercial success, impacting health outcomes positively.
What makes Canada special in terms of talent for the life sciences sector, and what are the challenges in finding the right talent?
Canada is globally recognized for its excellence in research and science, tracing back to discoveries like insulin. This reputation is upheld by our universities, which produce exceptional scientists, including Nobel laureates. This scientific prowess is attractive to investors, especially from the U.S., who value the grounded and proven nature of Canadian science. However, the biotech industry is a global one, growing rapidly and requiring specialized talent like scientists, researchers, and lab technicians. The challenge for Canada, like many countries, is not only to retain our homegrown talent but also to attract international talent to support the growth of our sector. Talented individuals are often drawn to global hubs, like Boston, for opportunities. Therefore, our focus is on both nurturing our talent pool and enhancing our attractiveness to global talent, essential for the advancement of our biotech companies. This is why creating anchor companies around which clusters grow, is so important.
How do you see the role of AI in the life sciences industry, and will it affect the need for traditional talent?
Artificial Intelligence (AI) is becoming increasingly significant in life sciences, particularly in areas like drug discovery and development. It holds the potential to streamline processes, reduce timeframes, and make certain lab tasks more efficient. However, this technological advancement does not diminish the need for talent; instead, it shifts the focus. The burgeoning AI sector, especially in biotech, requires highly skilled and educated individuals.
So, while AI might reduce the need for certain traditional roles, it simultaneously creates a demand for new types of expertise. This shift represents a transition of skill sets rather than an outright reduction in the need for talent.
Can you highlight some exciting innovations happening within your member companies?
Our member companies, numbering 240, are diverse and innovative, making it challenging to single out specific projects. Each company has its unique story and driving force, often born from a personal mission to address a specific health challenge or illness. This passion is evident across our member base, from start-ups to established entities. In terms of technological advancements, we’re witnessing groundbreaking work in biologic medicines, cell and gene therapies, and stem cell research. The development of mRNA vaccines, initially aimed at oncology but pivotally instrumental during the pandemic, is a testament to the sector’s innovation and impact. Canadian companies are also pioneering in areas like plant cell-based technologies for human applications and 3D printing for tissue creation in drug testing. These innovations aren’t just enhancing healthcare; they’re moving towards curing diseases.
What are the challenges for small biotech companies in securing capital and bringing a drug to market?
Securing investment capital is a paramount challenge for all early stage biotech companies, as it’s the fuel for their development engine. Drug discovery and development are costly and time-consuming processes, often requiring 10-15 years and up to 1.5 billion dollars. This long horizon demands patient investors with a deep understanding of science and significant financial resources. Despite a recent surge in investment, partly due to the pandemic’s highlighting of the sector’s importance, the challenge persists. Investors seek the best returns, often leading to global competition for capital. Unlike industries tied to physical resources like mining or oil, biotech ideas are mobile and can move to where the investment is. Canada, therefore, faces the dual challenge of retaining homegrown ideas and attracting international investment. This necessitates creating an attractive environment for investors, akin to a hotel enticing tourists with amenities. Canada must offer compelling incentives like tax returns, IP protections, and a stable environment to appeal to these ‘investor tourists.’ The goal is not just to attract capital but to foster an ecosystem where these innovative ideas can be developed and commercialized domestically, maximizing their economic and societal benefits.
In Canada’s complex economic system, how do you perceive the role of policy in supporting the life sciences ecosystem?
The Canadian life sciences ecosystem, especially in the context of small, early-stage companies, receives considerable support from local and provincial governments. These entities, emerging from universities like UBC or the University of Montreal, are viewed as valuable assets, contributing to local development and innovation. The pandemic has amplified this perception, highlighting the importance of nurturing our domestic sectors to prepare for future crises. However, a more holistic view of the ecosystem is needed. This includes not only these early-stage companies and investors but also global pharma companies. Public policy should aim to support this entire spectrum, recognizing the interdependence of different players within the ecosystem. It’s about creating an environment where all elements – from the small biotechs to the multinational pharma – are integrated and supported through comprehensive public policies.
What is the public perception in Canada of the pharma industry, and how does it relate to the understanding of drug costs and risks?
The public perception of the pharma industry in Canada varies greatly. For those untouched by serious illness, drug costs can seem exorbitant. In contrast, individuals whose lives have been changed by these drugs often express profound gratitude. This dichotomy underscores the personal nature of healthcare. The relationship between the pharma industry and payers, mainly the government in Canada, has traditionally been strained, centered around pricing and reimbursement. However, the pandemic has fostered a more collaborative approach, with governments recognizing the complexity and cost involved in drug development and the industry acknowledging the financial strains on healthcare systems. This has opened doors to more creative pricing models and a partnership-driven approach, marking a positive shift in the industry-government relationship.
Looking ahead, what are the major challenges and goals for BIOTECanada and the Canadian life sciences sector?
Our primary challenges remain consistent: securing investment and attracting talent. However, a cross-cutting issue that we see is regulatory adaptation to emerging technologies. As we embrace AI in drug discovery and healthcare delivery, and as data becomes more central to our processes, regulators need to evolve their understanding and frameworks to keep pace with these advancements. The challenge lies in maintaining safety and efficacy standards while embracing new technologies. This is a significant hurdle, but also a great opportunity, with signs of willingness from both the industry and government to navigate this new terrain together. It’s about striking a balance where regulations support innovation while ensuring public safety and efficacy.
What is the future vision for BIOTECanada, and what excites you about the coming years?
Our vision for BIOTECanada is to reflect and foster the growth of the Canadian biotech ecosystem. Ideally, we would like to see our membership and revenue base double in the next five years, indicating a thriving industry. A crucial aspect of our vision is the establishment of Canadian biotech anchor companies – commercial entities with a global presence, rooted in Canadian cities. These anchor companies would not only signify commercial success but also catalyze broader ecosystem growth, attracting more investment and talent. A comparison can be drawn with Denmark’s Novo Nordisk, a company that has significantly impacted its national economy. We envision similar success stories in Canada, with companies like AbCellera Biologics Inc. in Vancouver and Repare Therapeutics in Montreal leading the way. The goal is to transition from a landscape dotted with promising startups to one anchored by globally competitive, Canadian-headquartered biotech firms.
View original article here